English Spanish Chinese Russian German Japanese Portuguese Hindi Telugu Tamil

Annales de la recherche clinique et de laboratoire

  • ISSN: 2386-5180
  • Indice h du journal: 17
  • Note de citation du journal: 6.26
  • Facteur d’impact du journal: 5.31
Indexé dans
  • Genamics JournalSeek
  • Infrastructure nationale des connaissances en Chine (CNKI)
  • CiteFactor
  • Répertoire d'indexation des revues de recherche (DRJI)
  • Publions
  • Pub européen
  • Google Scholar
  • SHERPA ROMÉO
  • Laboratoires secrets des moteurs de recherche
Voir plus
Partager cette page

Abstrait

Convalescent Plasma Therapy for Prophylaxis and Treatment of COVID-19: A Systematic Research of Facts and Files, A Narrative Review

Koduri Sridevi, Amit Munjal, Ajay Chandran, Nachiappan S,Praveena Raman, Sukriti Bhalla, Sourya Kumar, Abhishek Singh Nayyar

Humanity has witnessed a pandemic in late December or, early January. Novel corona virus nCov-19 is responsible for causing COVID-19. The first case was reported in Wuhan city, China in the month of December 2019. No specific drugs have been approved yet for its treatment, though, convalescent plasma (CP) therapy is expected to increase the survivable rate. The history of convalescent plasma therapy dates back to the early 20th century. A plethora of studies suggest that CP can be used to treat the emerging infectious diseases. We had a systematic search in PubMed and found numerous Chinese and Korean clinical trials of convalescent plasma transfusions. The present review gives an insight in to the same.

Avertissement: Ce résumé a été traduit à l'aide d'outils d'intelligence artificielle et n'a pas encore été examiné ni vérifié